Do you recommend adjuvant capecitabine for a very small amount (2 mm, ypT1a) of residual invasive disease in TNBC patients following neoadjuvant chemotherapy and lumpectomy?  

The data regarding TNBC neoadjuvant cases who attain an RCB1 response suggests they do almost as well as RCB0 pCR patients. (Symmans et al JCO) so the absolute impact of adjuvant xeloda will probably be minimal and not worth the toxicity. It is of more benefit in those with RCB2 disease. The CREATEX...